Abnormal Interpretations

Abnormal Interpretations by Indication for Examination for 401,548 Diagnostic Mammography Examinations from 2007 - 2013

Based on BCSC data through 2013

  Work-Up of Abnormal Screening Exams Short-Interval  Follow-Up Evaluation of Breast Problem/ No Lump or Lump Unknown Evaluation of Breast Problem/ Palpable Lump All Diagnostic Exams
Abnormal Interpretation Rate* 17.00% 5.20% 9.30% 18.70% 12.60%
Abnormal final interpretations 21,941 2,672 6,941 6,615 50,659
All examinations 128,976 51,440 74,426 35,308 401,548
PPV2 26.90% 19.60% 26.70% 34.50% 27.50%
Cancers 5,909 525 1,853 2,279 13,915
Abnormal final interpretations 21,941 2,672 6,941 6,615 50,659
PPV3§ 29.20% 23.40% 31.00% 37.70% 30.40%
Cancers 5,726 505 1,760 2,143 10,725
Abnormal final interpretations, with known biopsy 19,621 2,158 5,681 5,687 35,275
Notes:
Numbers are frequencies unless otherwise indicated.
The first non-zero assessment within 90 days was used as the final assessment for analysis.
**  Includes 94,228 exams from one registry for which sub-classification of diagnostic indication (e.g., additional evaluation, short interval follow-up, etc.) was not available.
*  Abnormal interpretation rate = the percentage of examinations with an abnormal final interpretation
(BI-RADS category 4 or 5; Note: 0 or 3 with a recommendation for biopsy was recoded as 4).
  PPV2 = the percentage of examinations with an abnormal final interpretation
that result in a tissue diagnosis of cancer within 1 year.
§  PPV3 = the percentage of examinations with an abnormal final interpretation,
where it is known that a biopsy was performed as a result of the abnormal diagnostic examination,
that result in a tissue diagnosis of cancer within 1 year. (Excludes Chicago)
Table numbers last updated Mar 26, 2017. 

The following must be cited when reproducing this data:

"The Breast Cancer Surveillance Consortium and its data collection and sharing activities are funded by grants from the National Cancer Institute (P01CA154292, U54CA163303), Patient-Centered Outcomes Research Institute (PCS-1504-30370), and Agency for Health Research and Quality (R01 HS018366-01A1). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - http://www.bcsc-research.org/. More information regarding the BCSC is available at: http://bcsc-research.org/."